Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions

Area of Science:

• Nephrology
• Hematology
• Clinical Pharmacology

Background:

• Current anemia management guidelines for chronic kidney disease (CKD) rely on limited evidence regarding intravenous (IV) iron therapy.
• The Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guideline requires updates based on new research.

Purpose of the Study:

• To discuss the implications of recent randomized clinical trials (FIND-CKD, REVOKE) and observational studies on IV iron therapy in CKD.
• To identify critical evidence gaps in the use of IV iron for managing anemia in CKD patients.

Main Methods:

• Review and synthesis of findings from completed randomized clinical trials (FIND-CKD, REVOKE).
• Inclusion of data from relevant observational studies.
• Consideration of results from the ongoing PIVOTAL clinical trial.

Main Results:

• Recent trials provide new data on the efficacy and safety of IV iron in CKD anemia.
• The evidence base for IV iron therapy in CKD is expanding beyond the 2012 KDIGO guidelines.
• Ongoing trials like PIVOTAL are expected to further inform clinical practice.

Conclusions:

• Existing recommendations for IV iron in CKD anemia need re-evaluation in light of new trial data.
• Further research is necessary to address remaining evidence gaps and optimize IV iron use.
• Clinical practice should consider emerging evidence for managing anemia in CKD patients.